Blueprint Medicines Corp. (NASDAQ:BPMC) saw an uptick in trading volume on Tuesday . 251,889 shares were traded during trading, an increase of 15% from the previous session’s volume of 218,180 shares.The stock last traded at $21.39 and had previously closed at $21.10.

A number of research firms have commented on BPMC. Raymond James Financial Inc. began coverage on shares of Blueprint Medicines Corp. in a research report on Friday, May 27th. They set an “outperform” rating and a $23.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $41.00 price objective on shares of Blueprint Medicines Corp. in a research report on Tuesday, March 15th. Zacks Investment Research raised shares of Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Thursday, March 17th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Blueprint Medicines Corp. in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.50.

The company has a 50 day moving average price of $19.52 and a 200-day moving average price of $18.13. The company’s market capitalization is $579.46 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its earnings results on Tuesday, May 10th. The company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.13. The company earned $6.90 million during the quarter, compared to analyst estimates of $3.24 million. The firm’s quarterly revenue was up 961.5% compared to the same quarter last year. On average, equities analysts anticipate that Blueprint Medicines Corp. will post ($3.10) earnings per share for the current fiscal year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the company’s stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $20.03, for a total value of $340,510.00. Following the transaction, the chief executive officer now owns 92,486 shares of the company’s stock, valued at $1,852,494.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christoph Lengauer sold 15,872 shares of the company’s stock in a transaction dated Wednesday, April 13th. The shares were sold at an average price of $20.01, for a total transaction of $317,598.72. Following the completion of the transaction, the insider now directly owns 56,657 shares in the company, valued at approximately $1,133,706.57. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Blueprint Medicines Corp. stock. Casdin Capital LLC purchased a new stake in Blueprint Medicines Corp. (NASDAQ:BPMC) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 412,500 shares of the company’s stock, valued at approximately $10,865,000. Blueprint Medicines Corp. comprises about 9.6% of Casdin Capital LLC’s holdings, making the stock its largest position. Casdin Capital LLC owned approximately 1.52% of Blueprint Medicines Corp. at the end of the most recent reporting period.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.